Neuroendocrine Tumor Clinical Trial
Official title:
Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor
This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with Neuroendocrine Tumor
Octreotide is an artificial replacement for the natural growth hormone inhibitor in humans. It is a small peptide hormone consisting of 14 amino acids and is widely distributed in neuroendocrine cells, with the highest density in the brain, peripheral neurons, endocrine pancreas and gastrointestinal tract. Under pathological conditions, some tumour cells show overexpression of growth inhibitory receptors, such as endocrine tumours of the pancreas, pituitary adenomas, pheochromocytomas, paragangliomas, carcinoid tumours, medullary thyroid carcinomas, small cell lung carcinomas and other neuroendocrine tumours. Therefore, the sensitivity and specificity of octreotide imaging is high. This study will provide a visual, reproducible and non-invasive imaging method for the diagnosis of neuroendocrine tumours through Al18F-octreotide PCT/CT imaging, providing an intuitive and clear imaging basis for clinical diagnosis, differential diagnosis and treatment, contributing to the development of medicine and science in the field of positron imaging. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04837885 -
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
|
Phase 2 | |
| Completed |
NCT00789841 -
Gastrointestinal Motility in Patients With Neuroendocrine Tumors
|
N/A | |
| Recruiting |
NCT05069220 -
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
|
Early Phase 1 | |
| Completed |
NCT05816720 -
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
|
||
| Active, not recruiting |
NCT04400474 -
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
|
Phase 2 | |
| Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
| Completed |
NCT01849523 -
Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study
|
N/A | |
| Recruiting |
NCT01448083 -
Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours
|
N/A | |
| Completed |
NCT00804336 -
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02092714 -
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
|
||
| Terminated |
NCT04073017 -
Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency
|
N/A | |
| Completed |
NCT00434109 -
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
|
Phase 2 | |
| Completed |
NCT02481804 -
Optimal Feeding for NET Patients
|
N/A | |
| Completed |
NCT02472678 -
Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor
|
N/A | |
| Completed |
NCT02147106 -
Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study
|
N/A | |
| Completed |
NCT00165230 -
Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT03012789 -
Surgical Intervention and the NETest
|
N/A | |
| Not yet recruiting |
NCT02038738 -
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT01024387 -
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
| Terminated |
NCT00227617 -
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
|
Phase 2/Phase 3 |